WO2001018542A3 - Identification, assessment, prevention, and therapy of ovarian cancer - Google Patents

Identification, assessment, prevention, and therapy of ovarian cancer Download PDF

Info

Publication number
WO2001018542A3
WO2001018542A3 PCT/US2000/024199 US0024199W WO0118542A3 WO 2001018542 A3 WO2001018542 A3 WO 2001018542A3 US 0024199 W US0024199 W US 0024199W WO 0118542 A3 WO0118542 A3 WO 0118542A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
assessment
therapy
prevention
identification
Prior art date
Application number
PCT/US2000/024199
Other languages
French (fr)
Other versions
WO2001018542A2 (en
Inventor
John Lee
Pamela Thompson
James Lillie
Original Assignee
Millennium Predictive Medicine
John Lee
Pamela Thompson
James Lillie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Predictive Medicine, John Lee, Pamela Thompson, James Lillie filed Critical Millennium Predictive Medicine
Priority to AU77011/00A priority Critical patent/AU7701100A/en
Publication of WO2001018542A2 publication Critical patent/WO2001018542A2/en
Publication of WO2001018542A3 publication Critical patent/WO2001018542A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries

Abstract

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human ovarian cancers. A variety of markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of ovarian cancer.
PCT/US2000/024199 1999-09-03 2000-09-01 Identification, assessment, prevention, and therapy of ovarian cancer WO2001018542A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU77011/00A AU7701100A (en) 1999-09-03 2000-09-01 Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US15254799P 1999-09-03 1999-09-03
US60/152,547 1999-09-03
US19034700P 2000-03-16 2000-03-16
US60/190,347 2000-03-16
US19132100P 2000-03-21 2000-03-21
US60/191,321 2000-03-21
US20838200P 2000-05-31 2000-05-31
US60/208,382 2000-05-31
US22046700P 2000-07-20 2000-07-20
US60/220,467 2000-07-20

Publications (2)

Publication Number Publication Date
WO2001018542A2 WO2001018542A2 (en) 2001-03-15
WO2001018542A3 true WO2001018542A3 (en) 2001-11-22

Family

ID=27538427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024199 WO2001018542A2 (en) 1999-09-03 2000-09-01 Identification, assessment, prevention, and therapy of ovarian cancer

Country Status (2)

Country Link
AU (1) AU7701100A (en)
WO (1) WO2001018542A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
AU2001283062A1 (en) 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns
AU2002241720A1 (en) * 2000-11-08 2002-06-18 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AT410673B (en) * 2001-03-22 2003-06-25 Red Bull Gmbh Detecting Alzheimer's disease and Down's syndrome, from underexpression of phosphoprotein ARPP-19, in tissue or body fluid
FR2826373A1 (en) * 2001-06-20 2002-12-27 Molecular Engines Laboratoires SEQUENCES INVOLVED IN THE PHENOMENA OF TUMOR DEPRESSION, TUMOR REVERSION APOPTOSIS AND / OR RESISTANCE TO VIRUSES AND THEIR USE AS MEDICAMENTS
WO2003010337A1 (en) * 2001-07-23 2003-02-06 Masaaki Oka Scoring system for the prediction of cancer recurrence
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
EP1310552B1 (en) 2001-11-09 2007-06-13 Proteologics, Inc. Posh nucleic acids, polypeptides and related methods
WO2003087372A2 (en) * 2002-04-12 2003-10-23 Molecular Engines Laboratories Growth factor derived from hepatome and the use of the same
CN1845999A (en) * 2003-07-02 2006-10-11 诺瓦提斯公司 Genes regulated in ovarian cancer as prognostic and therapeutic targets
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
SG190466A1 (en) * 2011-11-18 2013-06-28 Agency Science Tech & Res Methods for diagnosis and/or prognosis of ovarian cancer
CN114702566B (en) * 2022-03-29 2023-08-01 浙江大学 Small peptide encoded by long-chain non-coding RNA LINC01234 and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
WO1998041648A2 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO1998043092A1 (en) * 1997-03-24 1998-10-01 Baystate Medical Center Method for determining the presence of mutated brca protein
US5871941A (en) * 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
WO1999028471A2 (en) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242813A (en) * 1990-10-12 1993-09-07 The United States Of America As Represented By The Department Of Health And Human Services Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
US5871941A (en) * 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
WO1998041656A1 (en) * 1997-03-19 1998-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and method for the early diagnosis of ovarian cancer
WO1998041648A2 (en) * 1997-03-20 1998-09-24 Variagenics, Inc. Target genes for allele-specific drugs
WO1998043092A1 (en) * 1997-03-24 1998-10-01 Baystate Medical Center Method for determining the presence of mutated brca protein
WO1999028471A2 (en) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL HILLIER, L. ET AL.: "Generation and analysis of 280,000 human expressed sequence tags", XP002163306 *
HUFLEJT M E ET AL: "Galectin-4: A new marker for breast and well differentiated ovarian cancer.", BREAST CANCER RESEARCH AND TREATMENT, vol. 46, no. 1, October 1997 (1997-10-01), 20th Annual San Antonio Breast Cancer Symposium;San Antonio, Texas, USA; December 3-6, 1997, pages 103, XP000991229, ISSN: 0167-6806 *
RUDLOWSKI C ET AL: "Immunohistochemical expression of Glut-1 transport protein in primary ovarian cancer - A characteristic feature of the malignant phenotype.", GEBURTSHILFE UND FRAUENHEILKUNDE, vol. 59, no. 6, June 1999 (1999-06-01), pages 258 - 260, XP000991201, ISSN: 0016-5751 *
TAKAGI AKIYOSHI ET AL: "Macrophage colony-stimulating factor (M-CSF) production in vivo and in vitro in gynecologic malignancies.", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol. 4, no. 3, June 1999 (1999-06-01), pages 142 - 147, XP000991397, ISSN: 1341-9625 *
TANIMOTO HIROTOSHI ET AL: "The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment.", TUMOR BIOLOGY, vol. 20, no. 2, March 1999 (1999-03-01), pages 88 - 98, XP000991200, ISSN: 1010-4283 *
TANOS VASILIOS ET AL: "Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer.", EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, vol. 85, no. 1, July 1999 (1999-07-01), pages 7 - 11, XP000992185, ISSN: 0301-2115 *

Also Published As

Publication number Publication date
AU7701100A (en) 2001-04-10
WO2001018542A2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
AU2002324451A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2005032328A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
CA2288948A1 (en) Modified arginine deiminase
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
EP2051077A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002044360A3 (en) Modified arginine deiminase
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2005008251A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
WO2002085298A3 (en) Method for detecting breast cancer cells
AU5576601A (en) Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP